Abstract
Background The Remunity Pump for Remodulin (treprostinil) Injection is an infusion system indicated for use with subcutaneous treprostinil.
Objective The objective was to assess the stability of diluted treprostinil sodium stored in Remunity pump cassettes.
Methods Treprostinil’s chemical and physical stability were assessed over a 76-hour period at 40 degrees Celsius and 75% relative humidity after dilution to 0.01 mg/mL in sterile water for injection and 0.9% sodium chloride. Analyses were conducted via visual inspection, pH measurement, and a stability-indicating high-performance liquid chromatographic assay.
Results At all time points, the treprostinil samples were consistently clear, colorless, and free of visible particulate matter, with pH levels 6.0-7.0. All assays were within 90.0%-110.0% of the label claim, with minimal variation.
Conclusions Treprostinil diluted to 0.01 mg/mL was stable in Remunity pump cassettes for up to 76 hours at elevated temperature and humidity. No notable changes from label claim concentration values were observed.
Competing Interest Statement
DS is an employee of United Therapeutics Corp and declares support for the present manuscript; stock or stock options; and other financial or non-financial interests; all from United Therapeutics Corp. MRS is an employee of United Therapeutics Corp and declares support for the present manuscript; stock or stock options; and other financial or non-financial interests; all from United Therapeutics Corp. JHD is an employee of United Therapeutics Corp and declares support for the present manuscript; stock or stock options; and other financial or non-financial interests; all from United Therapeutics Corp. AML is an employee of Cambrex Corporation, which received payment for this work.
Funding Statement
United Therapeutics Corporation supported the research and manuscript development for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: United Therapeutics Corporation supported the research and manuscript development for this work.
Conflicts of interest and Source of Funding: DS is an employee of United Therapeutics Corp and declares support for the present manuscript; stock or stock options; and other financial or non-financial interests; all from United Therapeutics Corp.
MRS is an employee of United Therapeutics Corp and declares support for the present manuscript; stock or stock options; and other financial or non-financial interests; all from United Therapeutics Corp.
JHD is an employee of United Therapeutics Corp and declares support for the present manuscript; stock or stock options; and other financial or non-financial interests; all from United Therapeutics Corp.
AML is an employee of Cambrex Corporation, which received payment for this work.
Data Availability
All data produced in the present study are available upon reasonable request to the authors